%PDF-1.4
%
22 0 obj
<>
endobj
19 0 obj
<>
endobj
71 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-29T13:30:15Z
2024-03-28T18:07:51-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T18:07:51-07:00
application/pdf
Heather
200805.sept
uuid:1a63bb94-1dd2-11b2-0a00-eb08276d7200
uuid:1a63bb97-1dd2-11b2-0a00-b80000000000
endstream
endobj
8 0 obj
<>
endobj
9 0 obj
<>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
81 0 obj
[85 0 R]
endobj
82 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:9)Tj
0 Tw -46.2952 -0.0313 Td
(2102)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.0601 Tw 10 0 0 10 54 600.1551 Tm
(systemic onset subtype. Bloom, )Tj
/TT0 1 Tf
13.1833 0 Td
(et al)Tj
/TT1 1 Tf
0 Tw 6.5 0 0 6.5 203.9293 603.4551 Tm
(9)Tj
0.0601 Tw 10 0 0 10 210.2803 600.1551 Tm
(also observed a high)Tj
-0.00011 Tc 0.2524 Tw -15.628 -1.2 Td
[(rate of early relapse in systemic onset JIA. Conversely)64.8 (,)]TJ
0 Tc 0 Tw 0 -1.2 TD
(Honkanen, )Tj
/TT0 1 Tf
0.1693 Tw 4.7789 0 Td
(et al)Tj
/TT1 1 Tf
0 Tw 6.5 0 0 6.5 120.9771 579.4551 Tm
(10)Tj
0.1693 Tw 10 0 0 10 131.6699 576.1551 Tm
(reported that the onset subtype had no)Tj
0.1364 Tw -7.767 -1.2 Td
(predictive value in 79 patients with JIA, though only one)Tj
0.0323 Tw T*
(had systemic disease, and other investigators found a lower)Tj
-0.0058 Tw T*
(response rate in children with psoriatic arthritis and spondy-)Tj
0 Tw T*
(loarthropathy)Tj
6.5 0 0 6.5 107.8672 531.4551 Tm
(4,5)Tj
0.091 Tw 10 0 0 10 115.9921 528.1551 Tm
(. Allen, )Tj
/TT0 1 Tf
0.1459 Tw 3.4583 0 Td
(et al)Tj
/TT1 1 Tf
0 Tw 6.5 0 0 6.5 169.5299 531.4551 Tm
(4)Tj
-0.00011 Tc 0.146 Tw 10 0 0 10 176.739 528.1551 Tm
[(and Hertzber)17.7 (ger)19.7 (-ten Cate, )]TJ
/TT0 1 Tf
0 Tc 0 Tw [0.4 (et)]TJ
-12.2739 -1.2 Td
(al)Tj
/TT1 1 Tf
6.5 0 0 6.5 61.7783 519.4551 Tm
(6)Tj
0.1284 Tw 10 0 0 10 68.8127 516.1551 Tm
(reported a more durable response to IAC injections in)Tj
-0.00011 Tc 0.25191 Tw -1.4813 -1.2 Td
[(patients with shorter disease duration. )54.8 (Allen, )]TJ
/TT0 1 Tf
0 Tc [-0.5 (et al)]TJ
/TT1 1 Tf
0 Tw 6.5 0 0 6.5 269.6254 507.4551 Tm
(4)Tj
-0.00011 Tc 10 0 0 10 277.8943 504.1551 Tm
(also)Tj
0 Tc -0.0083 Tw -22.3894 -1.2 Td
(found a better response pattern in younger patients and boys)Tj
0.14619 Tw T*
[(with JIA. )54.9 (At variance, no correlation of the response rate)]TJ
0.0451 Tw T*
(with age was observed by Honkanen, )Tj
/TT0 1 Tf
0.0452 Tw 15.4601 0 Td
(et al)Tj
/TT1 1 Tf
0 Tw 6.5 0 0 6.5 226.5475 471.4551 Tm
(10)Tj
0.0452 Tw 10 0 0 10 233.0474 468.1551 Tm
[(, and Earley)64.9 (, )]TJ
/TT0 1 Tf
0 Tw 5.3736 0 Td
(et)Tj
-23.2783 -1.2 Td
(al)Tj
/TT1 1 Tf
6.5 0 0 6.5 61.7783 459.4551 Tm
(5)Tj
0.0172 Tw 10 0 0 10 67.7005 456.1551 Tm
(could not identify any association with the disease dura-)Tj
0.23599 Tw -1.3701 -1.2 Td
[(tion or patient age. )17.8 (These discrepancies may depend on)]TJ
-0.0081 Tw T*
[(dif)17.8 (ferences in study design, patient selection, indications for)]TJ
0.1494 Tw T*
[(the IAC therapy)64.9 (, corticosteroid preparation, type of joints)]TJ
0.1783 Tw T*
(injected, time when the injections were performed in the)Tj
0.10899 Tw T*
(course of the disease, and genetic heterogeneity of patient)Tj
0 Tw T*
(populations.)Tj
0.0647 Tw 1.2 -1.2 Td
[(W)79.8 (e found that a higher ESR was the strongest predictor)]TJ
0.06351 Tw -1.2 -1.2 Td
(of sustained complete clinical response to IAC injection of)Tj
0.0463 Tw T*
[(the knees. Dif)17.8 (ferences in cytokine profiles, )17.7 (T)-278.6 (cell infiltrate,)]TJ
0.0377 Tw T*
[(and )17.8 (T)-269.9 (cell clonality have been observed in the synovium of)]TJ
-0.00011 Tc 0.0386 Tw T*
[(children with JIA, suggesting that dif)17.7 (ferent ef)17.7 (fector mecha-)]TJ
0 Tc 0.2019 Tw T*
(nisms could be involved in the pathogenesis of synovial)Tj
0.09891 Tw T*
(inflammation in this disease)Tj
-0.00011 Tc 0 Tw 6.5 0 0 6.5 169.4384 303.4551 Tm
[(1)56.6 (1-14)]TJ
0.099 Tw 10 0 0 10 184.2326 300.1551 Tm
(. Our findings suggest that)Tj
0 Tc 0.14011 Tw -13.0233 -1.2 Td
[(JIA)-335.2 (patients who have higher ESR are characterized by a)]TJ
0.0753 Tw T*
(synovial inflammation process that is particularly sensitive)Tj
0.02499 Tw T*
(to corticosteroid injection.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT1 1 Tf
0.02499 Tw 8 0 0 8 61 230.1551 Tm
[(1.)-875.1 (Dent PB, )17.7 (W)79.7 (alker N. Intra-articular corticosteroids in the treatment)]TJ
0 Tc 1.675 -1.25 Td
(of juvenile rheumatoid arthritis. Curr Opin Rheumatol)Tj
0 Tw 0 -1.25 TD
(1998;10:475-80.)Tj
0.02499 Tw -1.675 -1.25 Td
[(2.)-875 (Petty RE, Southwood )17.8 (TR, Baum J, et al. Revision of the proposed)]TJ
1.675 -1.25 Td
(classification criteria for juvenile idiopathic arthritis: Durban, 1997.\
)Tj
T*
(J Rheumatol 1998;25:1991-4.)Tj
31.325 52.7843 Td
[(3.)-875 (Fantini F)79.8 (, Corvaglia G, Ber)17.8 (gomi P)110.8 (, et al. )17.7 (V)111.1 (alidation of the Italian)]TJ
1.675 -1.25 Td
[(version of the Stanford Childhood Health )54.9 (Assessment)]TJ
T*
(Questionnaire for measuring functional status in children with)Tj
T*
(chronic arthritis. Clin Exp Rheumatol 1995;13:785-91.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Allen RC, Gross KR, Laxer RM, Malleson PN, Beauchamp RD,)]TJ
0 Tc 1.675 -1.25 Td
(Petty RE. Intraarticular triamcinolone hexacetonide in the)Tj
T*
[(management of chronic arthritis in children. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1986;29:997-1001.)Tj
0.0249 Tw -1.675 -1.25 Td
[(5.)-875 (Earley )54.8 (A, Cuttica RJ, McCullough C, )54.8 (Ansell BM. )17.7 (T)34.9 (riamcinolone)]TJ
1.675 -1.25 Td
(into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol)Tj
0 Tw T*
(1988;6:153-5.)Tj
0.0249 Tw -1.675 -1.25 Td
[(6.)-875 (Hertzenber)17.8 (ger)19.8 (-ten Cate R, de )17.7 (V)60.1 (ries-van der )17.7 (Vlugt BCM, van)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(Suijlekom-Smit L)73.9 (W)110.7 (A, Cats )54.8 (A. Intra-articular steroids in)]TJ
0 Tc T*
(pauciarticular juvenile chronic arthritis, type 1. Eur J Pediatr)Tj
0 Tw T*
(1991;150:170-2.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Padeh S, Passwell JH. Intraarticular corticosteroid injection in the)]TJ
0 Tc 1.675 -1.25 Td
[(management of children with chronic arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1998;41:1210-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Breit )17.7 (W)91.7 (, Meyer )17.7 (V)129 (,)-0.1 ( Heinecke )54.8 (A, Frosch M, Ganser G. Subgroup)]TJ
0 Tc 1.675 -1.25 Td
(specific evaluation of multiple joint intra-articular triamcinolone)Tj
T*
(hexacetonide injections in juvenile chronic arthritis [abstract]. Clin)Tj
T*
(Exp Rheumatol 1995;13:559.)Tj
-1.675 -1.25 Td
[(9.)-875 (Bloom BJ, Miller LC, )17.7 (T)34.9 (ucker LB, )54.8 (Alario )54.8 (AJ, Schaller JG. Intra-)]TJ
-0.00011 Tc 1.675 -1.25 Td
(articular corticosteroids in juvenile chronic arthritis [abstract].)Tj
0 Tc T*
(Arthritis Rheum 1997;39 Suppl:S46.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Honkanen )17.7 (VEA, Rautonen JK, Pelkonen PM. Intra-articular)]TJ
0 Tc 2.175 -1.25 Td
[(glucocorticoids in early juvenile chronic arthritis. )54.8 (Acta Paediatr)]TJ
0 Tw T*
(1993;82:1072-4.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Murray KJ, Grom )54.8 (AA, )17.7 (Thompson SD, Lieuwen D, Passo MH,)]TJ
2.1381 -1.25 Td
(Glass DN. Contrasting cytokine profiles in the synovium of)Tj
0 Tc T*
[(dif)17.8 (ferent forms of juvenile rheumatoid arthritis and juvenile)]TJ
T*
(spondyloarthropathy: prominence of interleukin 4 in restricted)Tj
T*
(disease. J Rheumatol 1998;25:1388-98.)Tj
-2.175 -1.25 Td
[(12.)-875 (De Benedetti F)79.8 (, Ravelli )54.8 (A, Martini )54.8 (A. Cytokines in juvenile)]TJ
2.175 -1.25 Td
(rheumatoid arthritis. Curr Opin Rheumatol 1997;9:428-33.)Tj
-2.175 -1.25 Td
[(13.)-875 (Murray KJ, Luyrink L, Grom )54.8 (AA, et al. Immunohistological)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(characteristics of )17.7 (T)-257.3 (cell infiltrates in dif)17.7 (ferent forms of childhood)]TJ
0 Tc T*
[(onset chronic arthritis. J Rheumatol 1996;23:21)36.9 (16-24.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Thompson SD, Grom )54.8 (AA, Bailey S, et al. Patterns of )17.7 (T)-257.3 (lymphocyte)]TJ
0 Tc 2.175 -1.25 Td
(clonal expansion in HLA-typed patients with juvenile rheumatoid)Tj
T*
(arthritis. J Rheumatol 1995;22:1356-64.)Tj
/TT0 1 Tf
-26.55 63.775 Td
[(T)92 (able 2.)]TJ
/TT1 1 Tf
3.4858 0 Td
(Best predictor model from multivariate logistic regression analysis.)Tj
-3.4858 -2.5 Td
[(Predictor )17.7 (V)111.1 (ariables in the \223Best-fit\224 Model)-6585.3 (Odds Ratio)-4870.1 (95% CI)-5433.7 (p)]TJ
0 Tw 5.2 0 0 5.2 464.3 695.2693 Tm
(\206)Tj
0.0249 Tw 8 0 0 8 126 672.6293 Tm
(ESR \(> 20 mm/h\))Tj
25.22601 0 Td
(2.61)Tj
7.575 0 Td
[(0.99\2266.89)-4275 (0.049)]TJ
-32.80101 -1.25 Td
(Number of knees injected \(2 vs one\))Tj
25.22731 0 Td
(2.37)Tj
7.575 0 Td
(0.72\2267.74)Tj
-32.80231 -1.25 Td
(Involvement of other joints beside knees \(yes/no\))Tj
25.22871 0 Td
(0.89)Tj
7.57499 0 Td
(0.32\2262.49)Tj
0 Tw 5.2 0 0 5.2 126 635.2693 Tm
(\206)Tj
0.02499 Tw 8 0 0 8 130.8 632.6293 Tm
(Likelihood ratio test.)Tj
ET
128 706.1 m
484.8 706.1 l
126 686.3 m
484.8 686.3 l
126 645.5 m
484.8 645.5 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
64 0 obj
<>
endobj
76 0 obj
<>
endobj
25 0 obj
<>
endobj
33 0 obj
<>
endobj
32 0 obj
<>
endobj
30 0 obj
<>
endobj
54 0 obj
<>stream
HdVpTs͋р,1$^X$@RY
Z%&y H2H:#(*A0[